Ireland
--:--IST
Latest
Clinical Trials in France / NCT07449520
Starting soon Observational

Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)

NCT07449520 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2026-03
Last updated
2026-03-04

Condition(s) studied

Obesity

Investigational drug(s) / intervention(s)

Endoscopic sleeve gastroplasty

Endoscopic sleeve gastroplasty: Endoscopic sleeve gastroplasty is performed using a CE marked endoscopic suture device which allows for a reduction in stomach volume without resection or anastomosis

Study summary

EGO-Trial is the first multicenter study in France which aims to evaluate the efficacy of Endoscopic Sleeve Gastroplasty (ESG) in patients with obesity. This project fills a critical national gap by providing real-world, multicentric data from diverse French healthcare settings, offering insight into the safety, efficacy, and variability of ESG practices across institutions

The project is expected to generate robust, multicentric clinical evidence on the safety and efficacy of ESG in patients with obesity within the French healthcare context.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Patients aged 18 to 75 years. * Patients with a Body Mass Index (BMI) ≥ 30 kg/m². * Patients who have failed non-surgical weight loss interventions (diet, exercise, pharmacological therapy). * Patients not eligible for bariatric surgery or does not wish to undergo it. * Patients who can undergo general anesthesia. * Patients who are able to participate in all aspects of the study and agree to comply with all study requirements for the entire duration of the study. * Patients who are able to fully understand the study and are willing to give their consent to participate in the study. * Patients affiliated with the French social security system. Exclusion Criteria: * Patients with contraindications to endoscopic gastroplasty * Patients with active peptic ulcer disease or significant gastroparesis * Patients with a history of bariatric, gastric, or esophageal surgery. * Patients who have started medication in the last 3 months that is known to cause weight gain. * Patients with a history of uncontrolled, poorly controlled, or suspected eating disorders or psychiatric illness. * Patients with unstable and precarious health, as determined and assessed by the investigator. * Patients who are pregnant, breastfeeding, or of childbearing age and not using effective contraception. * Patients who are currently excluded (as determined by a previous or ongoing study). * Patients under judicial protection. * Patients under guardianship, conservatorship or subject to any form of protective supervision

Primary outcome measure(s)

Trial sites (10)

FacilityCityRegionStatus
Hôpital Privé de Provence Aix-en-Provence France
Polyclinique de Franche-Comté Besançon France
Clnique des Cèdres Échirolles France
Hôpital HURIEZ Lille France
Hospices Civils de Lyon - Hôpital Edourard HERRIOT Lyon France
Clinique Clémentville Montpellier France
Centre Mutualiste de l'Obésité Saint-Etienne France
Polyclinique Sainte Thérèse Sète France
Hôpitaux Universitaires de Strasbourg, Nouvel Hôpital Civil Strasbourg France
Clinique les Eaux Claires Baie-Mahault Guadeloupe

More IHU Strasbourg trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07449520 on ClinicalTrials.gov ↗ ← All trials in France